DaShenLin Pharmaceutical Group Co., Ltd. is a pharmaceutical company based in China with a risk rating score of 42.0, indicating severe risk. Specializing in Chinese herbal medicine, antibiotics, and biochemical drugs, DaShenLin is known for its pharmacy chain development. Their ESG score reflects their commitment to sustainability and governance. With operations primarily in China, the company is involved in pharmaceutical manufacturing, retail, and wholesale business.